temozolomide has been researched along with Leucocythaemia in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the tolerability, pharmacokinetics, and mechanisms of temozolomide resistance in children with relapsed or refractory leukemia." | 9.12 | Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. ( Adamson, PC; Berg, SL; Blaney, SM; Delaney, SM; Dolan, ME; Hedge, M; Horton, TM; Ingle, AM; Thompson, PA; Weiss, HL; Wu, MF, 2007) |
| "To determine the tolerability, pharmacokinetics, and mechanisms of temozolomide resistance in children with relapsed or refractory leukemia." | 5.12 | Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. ( Adamson, PC; Berg, SL; Blaney, SM; Delaney, SM; Dolan, ME; Hedge, M; Horton, TM; Ingle, AM; Thompson, PA; Weiss, HL; Wu, MF, 2007) |
| " A pilot clinical study indicates that dacarbazine can induce a marked decrease of leukemic blasts in patients affected by acute myelogenous leukemia (AML) with low pretreatment levels of OGAT activity." | 5.08 | Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. ( Bonmassar, E; Caravita, T; D'Atri, S; Franchi, A; Graziani, G; Papa, G; Piccioni, D, 1995) |
| " We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ)." | 4.82 | Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. ( Chang, MC; Chiang, MF; Hsieh, RK; Su, YW, 2005) |
| "treatment with Lomeguatrib (to suppress MGMT activity) and Temozolomide (to kill sensitive blasts and to presumably induce CX in resistant leukaemic cells); (b) immune response recovery phase using interleukin-2 (to possibly restore an immune response and take advantage of the hypothetical, triazene-induced CX)." | 1.34 | Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia. ( Alvino, E; Amadori, S; Bonmassar, E; Buccisano, F; Caporaso, P; D'Atri, S; Garbin, A; Marchesi, F; Tirindelli, MC; Toppo, L; Tortorelli, G; Turriziani, M; Venditti, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horton, TM | 2 |
| Jenkins, G | 1 |
| Pati, D | 1 |
| Zhang, L | 1 |
| Dolan, ME | 2 |
| Ribes-Zamora, A | 1 |
| Bertuch, AA | 1 |
| Blaney, SM | 2 |
| Delaney, SL | 1 |
| Hegde, M | 1 |
| Berg, SL | 2 |
| Rizzieri, D | 1 |
| LoRusso, S | 1 |
| Tse, W | 1 |
| Khan, K | 1 |
| Advani, A | 1 |
| Moore, J | 1 |
| Karsten, V | 1 |
| Cahill, A | 1 |
| Gerson, SL | 1 |
| Cipak, L | 1 |
| Su, YW | 1 |
| Chang, MC | 1 |
| Chiang, MF | 1 |
| Hsieh, RK | 1 |
| Katsoulas, A | 1 |
| Rachid, Z | 1 |
| Brahimi, F | 1 |
| McNamee, J | 1 |
| Jean-Claude, BJ | 1 |
| Caporaso, P | 1 |
| Turriziani, M | 2 |
| Venditti, A | 1 |
| Marchesi, F | 1 |
| Buccisano, F | 1 |
| Tirindelli, MC | 1 |
| Alvino, E | 1 |
| Garbin, A | 1 |
| Tortorelli, G | 1 |
| Toppo, L | 1 |
| Bonmassar, E | 5 |
| D'Atri, S | 4 |
| Amadori, S | 1 |
| Thompson, PA | 1 |
| Adamson, PC | 1 |
| Ingle, AM | 1 |
| Delaney, SM | 1 |
| Hedge, M | 1 |
| Weiss, HL | 1 |
| Wu, MF | 1 |
| Tentori, L | 3 |
| Graziani, G | 4 |
| Gilberti, S | 1 |
| Lacal, PM | 2 |
| Piccioni, D | 1 |
| Papa, G | 1 |
| Caravita, T | 1 |
| Franchi, A | 1 |
| Orlando, L | 1 |
| Benincasa, E | 1 |
| Faraoni, I | 1 |
| Franco, D | 1 |
| Serafino, A | 1 |
| Levati, L | 1 |
| Roy, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study Of Cloretazine™ (VNP40101M) And Temozolomide In Patients With Hematologic Malignancies[NCT00098436] | Phase 1 | 25 participants (Anticipated) | Interventional | 2004-09-30 | Completed | ||
| A Phase I Trial Of Temozolomide In Pediatric Patients With Refractory/Recurrent Leukemias[NCT00083070] | Phase 1 | 16 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for temozolomide and Leucocythaemia
| Article | Year |
|---|---|
Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
Topics: Acute Disease; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosomes, | 2005 |
3 trials available for temozolomide and Leucocythaemia
| Article | Year |
|---|---|
Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Histor | 2010 |
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; DNA Modi | 2007 |
Cisplatin increases sensitivity of human leukemic blasts to triazene compounds.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cisplatin; Dacarbazine; D | 1995 |
7 other studies available for temozolomide and Leucocythaemia
| Article | Year |
|---|---|
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repai | 2009 |
Novel nonclassical antifolate, 2-[N-(2´-Hydroxyethyl)amino]methyl-3H-quinazolin-4-one, with a potent antineoplastic activity toward leukemia cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Cisplatin; Dacarbazine; Female | 2012 |
Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Culture Media; Dacarbazine; DNA Damage; Dose-Response Re | 2005 |
Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia.
Topics: Animals; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; DNA Methylation; | 2007 |
Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Gene Expression; Humans; Leukemia; Methyl | 1995 |
Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; DNA Fragmentation; DNA Methylation; DNA R | 1997 |
Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzamides; Dacarbazine; DNA Glycosylases; DNA Ligases | 1999 |